Psychoeducation – the missing part of antidepressive treatment Review article
Article Sidebar
Main Article Content
Abstract
Depression is a disease of the multi-dimensional and heterogeneous in their course. Despite getting a better knowledge of pathomechanisms and increasing knowledge about the etiology of affective disorders we are still losing in this unequal fight. The first hurdle are somatic diseases, then the personality of the patient, the accompanying anxiety disorders or neurological diseases. Another problem is the fact that over the last decade we have had no significant findings in the pharmacotherapy of depression. And patients requirements become more clearly and boldly. Pharmacological treatment should be safe, well tolerated and also effective, which is really fulfil only in a few of antidepressants (e.g. the escitalopram). Therefore so important seem to be any additional action that can improve and accelerate the process of treatment of depression. The simplest, but also the most underestimated method is psychoeducation, which is able to secure, cooperation in the process of healing and stop the recurrence of affective disorders and it seems the most important from a prognostic point of view. Thus it is better able to protect patients from one of the worst complications of mood disorders, being invalid and thus falling out of role: life, social and economic.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Kessler RC, Zhao S, Blazer DG, Swart M. Prevalence, correlates, and course of minor depression and major depression in the National Comorbidity Survey. J Affect Disord 1997; 45: 19-30.
3. Łoza B, Parnowski T. Nowa depresja. Nowe leczenie. Medical Education, Warszawa 2012: 56-58.
4. Kessler RC, Berglund P, Demler O et al. The epidemiology of major depressive disorder: report from the National Comorbidity Survey Replication (NCS-R). Journal of the American Medical Association 2003; 289: 3095-3105.
5. Posner JA, DeBattista C, Williams GH et al. 2-Hour monitoring of cortisol and corticotropin secretion in psychotic and nonpsychotic major depression. Arch Gen Psychiatry 2000; 57: 755-760.
6. Wright P, Stern J, Phelan M. Sedno Psychiatria; t. I. Urban & Partner, Wrocław 2008: 287-311.
7. Brown ES, Suppes T. Mood symptomps during corticosteroid therapy: a review. Harv Rev Psychiatry 1996; 5: 239-246.
8. Lortis JM, Hauser P: The phenomenology and treatment of interferon-induced depression. J Affect Disord 2004; 82: 175-190.
9. O’Brien SM, Scott LV, Dinan TG. Cytokines: abnormalities in major depression and implications for pharmacological treatment. Hum Psychopharmacol 2004; 19: 397-403.
10. Raison CL, Capuron L, Miller AH. Cytokines sing the blues; inflamation and the phatogenesis of derpession. Trends Immunol 2006; 27: 24-31.
11. Asberg M, Thoren P, Traskman L et al. „Serotonin depression” – a biochemical subgroup within the affective disorders? Science 1976; 191: 478-480.
12. Mann JJ, Malone KM, Psych MR [sic] et al. Attempted suicide characteristic and cerebrospinal fluide amine metabolites in depressed inpatients. Neuropsychopharmacology 1996; 15: 576-586.
13. Nelsson JC. A review of the efficacy of serotonergic and noradrenergic reuptake inhibitors for treatment in major depression. Biol. Psychiatry 1999; 46: 1301-1308.
14. Polikowska M, Łoza B, Chorążka K et al. Obraz kliniczny i farmakoterapia depresji – przegląd dla lekarzy psychiatrów i lekarzy rodzinnych. Neuropsychiatria. Przegląd Kliniczny 2014; 6(1): 34-41.
15. Katon W. The epidemiology of depression in medical care. Int J Psychiatry Med 1987; 17: 93-112.
16. Pełka-Wysiecka J, Samochowiec J. Depresja – czy faktycznie zróżnicowana farmakoterapia? Psychiatria 2014; 11(3): 141-147.
17. Walsh F, Anderson CM. Chronic Disorders and the Family 1988.
18. Glick ID, Burti L, Okonogi K, Sacks M. Effectiveness in psychiatric care. III: Psychoeducation and outcome for patients with major affective disorder and their families. Br J Psychiatry 1994; 164: 104-106.
19. Tursi MF, Baes CV, Camacho FR et al. Effectiveness of psychoeducation for depression: a systematic review. Aust N Z J Psychiatry 2013; 47(11): 1019-31.
20. Morriss RK, Faizal MA, Jones AP et al. Interventions for helping people recognise early signs of recurrence in bipolar disorder. Cochrane Database Syst Rev 2007; (1): CD004854.
21. Morokuma I, Shimodera S, Fujita H et al. Psychoeducation for major depressive disorders: a randomised controlled trial. Psychiatry Res 2013; 210: 134-139.
22. Colom F, Vieta E, Sánchez-Moreno J et al. Group psychoeducation for stabilised bipolar disorders: 5-year outcome of a randomised clinical trial. Br J Psychiatry 2009; 194: 260-265.